Jayex share price plummets as revenues fall

ASX-listed health technology firm Jayex is confident it is still a going concern despite a 14 per cent fall in revenue and a flatlining share price.

Releasing its annual report to December 31 yesterday, the company, which earns most of its revenue from its UK arm, admitted that 2017 was a challenging year but its actual losses are less than the preceding period, when it reported a $4m impairment.

Posted in Australian eHealth

Tags: Jayex Healthcare

You need to log in to post comments. If you don't have a Pulse+IT website account, click here to subscribe.

Sign up for Pulse+IT eNewsletters

Sign up for Pulse+IT website access

For more information, click here.

Copyright © 2018 Pulse+IT Magazine
No content published on this website can be reproduced by any person for any reason without the prior written permission of the publisher.